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Abstract
Background: Recent works have suggested a possible link between interleukin (IL)-33 and B-cell biology. We
aimed to study the possible association between serum IL-33 detection and response to rituximab (RTX) in
rheumatoid arthritis (RA) patients in different cohorts with an accurate enzyme-linked immunosorbent assay
(ELISA).
Methods: Serum IL-33, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and high serum
immunoglobulin (Ig)G levels were assessed in 111 RA patients receiving a first course of 2 g RTX (cohort 1)
in an observational study and in 74 RA patients treated with the same schedule in routine care (cohort 2).
Univariate and multivariate analyses identified factors associated with a European League Against Rheumatism
(EULAR) response at 24 weeks.
Results: At week 24, 84/111 (76%) and 54/74 (73%) patients reached EULAR response in cohorts 1 and 2, respectively.
Serum IL-33 was detectable in only 33.5% of the patients. In the combined cohorts, the presence of RF or anti-CCP
(odds ratio (OR) 3.27, 95% confidence interval (CI) 1.13–9.46; p = 0.03), high serum IgG (OR 2.32, 95% CI 1.01–5.33;
p = 0.048), and detectable serum IL-33 (OR 2.40, 95% CI 1.01–5.72; p = 0.047) were all associated with RTX response in
multivariate analysis. The combination of these three factors increased the likelihood of response to RTX. When serum
IL-33 detection was added to seropositivity and serum IgG level, 100% of the patients with the three risk factors
(corresponding to 9% of the population) responded to RTX (OR versus patients with none of the three risk factors
29.61, 95% CI 1.30–674.79; p = 0.034).
Conclusion: Detectable serum IL-33 may predict clinical response to RTX independently of, and synergistically with,
auto-antibodies and serum IgG level.
Trial registration: NCT01126541; 18 May 2010.
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Background
Interleukin (IL)-33 is one of the most recently discov-
ered members of the IL-1 cytokine family mediating its
biological effects via its binding to its receptor suppres-
sion of tumorigenicity (ST)2 [1]. IL-33 is upregulated in
both resident cells and inflammatory infiltrating cells
and is released in case of cell injury, thus acting as an
alarmin [2, 3]. IL-33 induces production of Th2 cyto-
kines and eosinophilia, and may activate mast cells that
can in turn release several pro-inflammatory cytokines
[4]. IL-33 investigations have been mainly devoted to
asthma and allergy, with the development of a targeted
IL-33/ST2 axis therapeutic strategy [5].
IL-33 may also be involved in rheumatoid arthritis
(RA) pathogenesis. IL-33 administration exacerbates
collagen-induced and K/BxN serum-mediated murine
arthritis, and disease severity is reduced in mice treated
with sST2-Fc fusion protein or anti-IL-33 monoclonal
antibody [6–8]. Extracellular IL-33 is a critical enhancer
of tumor necrosis factor (TNF)-induced RA synovial
fibroblast activation [9] and could activate osteoclasto-
genesis [10, 11]. In patients with RA, biomarker studies
have suggested that the serum level of IL-33 could re-
flect clinical activity [12] and disease severity, or predict
carotid plaque progression [13]. However, the role of
IL-33 could be paradoxical since, in K/BxN serum
transfer-induced arthritis, ST2 but not IL-33 blockade
may improve arthritis [14, 15]. Moreover, IL-33-
stimulated mast cells could also suppress monocyte
activation [16] and intracellular IL-33 also has anti-
osteoclastogenic and anti-inflammatory properties [11].
Some recent works have suggested a possible link
between IL-33 and B-cell biology [17]. In mice, IL-33 en-
hances immunoglobulin (Ig)M synthesis and markedly
induces and activates B1 cells in an ST2-dependent
manner [18]. Additionally, IL-33 could also induce regu-
latory B cells to produce IL-10, attenuating mucosal
inflammation in the gut [19].
Using a transcriptomic approach, we have found that
increased IL-33 mRNA expression in the whole blood of
patients with RA was predictive of the response to ritux-
imab (RTX), a targeted B cell-depleting agent [20]. We
aimed to investigate, using an accurate and simple
enzyme-linked immunosorbent assay (ELISA), the pos-
sible association between a detectable serum level of the




A total of 224 patients with RA for at least 6 months
and fulfilling the American College of Rheumatology
(ACR) 1987 criteria were included in the SMART study
(NCT01126541). This study is a 2-year, national,
multicenter, randomized open-label study evaluating the
efficacy and tolerability of two doses of RTX for re-
treatment after one initial course of RTX at a usual dose
(1000 mg on days 1 and 15) described previously [21].
All patients had active disease, defined by a Disease
Activity Score in 28 joints (DAS28) using C-reactive pro-
tein (CRP) (DAS28-CRP) >3.2, with ≥6/66 swollen and
≥6/68 tender joints, or a CRP ≥10 mg/L, or an erythro-
cyte sedimentation rate (ESR) ≥28 mm/h. Erosive status
was based on the reading of hand and feet X-rays by the
investigators in each center. Each patient received a
stable dose of methotrexate (MTX) (≥10 mg/week for at
least 4 weeks) and had experienced an inadequate
response or intolerance to TNF inhibitors, or had con-
traindications to TNF inhibitors. All patients in the
SMART study received one course of RTX (two
1000 mg infusions, given on days 1 and 15) with usual
pre-medication (methylprednisolone, acetaminophen,
and antihistamine). In this ancillary study, 111 patients
from the 224 were included due to the availability of the
serum samples for IL-33 assessment and were desig-
nated as cohort 1.
We also studied 32 RA patients from Leeds (UK) and
42 from Clermont-Ferrand (France) treated in real life
with a first course of RTX using the same schedule. In
order to match the numbers of patients in cohort 1,
these two groups of patients from Leeds and Clermont-
Ferrand were merged and called cohort 2. There were
no overlaps between the two cohorts.
For all patients, treatment efficacy was evaluated 24 weeks
after the first RTX infusion according to European League
Against Rheumatism (EULAR) response [22]. Patients were
then classified as responders (good or moderate) or non-
responders after this first course of RTX.
Assessment of serum IL-33, auto-antibodies, and serum
IgG
We first used an ELISA IL-33 kit (DuoSet, R&D Sys-
tems) for protein assessment, and preliminary presented
as an abstract an association between serum IL-33 level
and RTX response in a single cohort [23]. However, this
kit was not validated for human sera and additional
experiments have confirmed the need for caution about
the accuracy of this kit for sera measurements [24].
Recommendations from the manufacturer advise us to
use another assay for human sera, named Quantikine
and also provided by R&D Systems. We aimed to use
this more accurate ELISA in order to investigate the
possible association between a detectable serum level of
IL-33 and a response to RTX in RA patients in the
different cohorts.
Using a sample obtained prior to the initiation of RTX
in the two cohorts, we measured the serum IL-33 level
using the Quantikine kit, which is a solid-phase ELISA
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with a 6.25 pg/mL lower limit threshold according to
the manufacturer’s instruction [24]. The assessment of
rheumatoid factor (RF), anti-cyclic citrullinated peptide
(anti-CCP) antibodies, and serum IgG level were also
performed. The upper limit of normal (ULN) for serum
IgG was 12.7 g/L and high serum IgG level was a value
above this cut-off, as described previously [25].
Statistical analysis
Continuous data are described as means and standard
deviations (mean ± SD) or as medians and ranges
(median (range)).
For all analyses, since serum IL-33 is not systematic-
ally detectable, we presented qualitative results as detect-
able serum IL-33 or undetectable serum IL-33. Among
patients of the SMART cohort, we compared patients
who were assessed for serum IL-33 level and those who
were not due to the availability of the serum samples.
Student and Wilcoxon tests were used to compare quan-
titative values and the Chi-squared test was used for
qualitative values.
We analyzed by logistic regression the relationship
between EULAR response at 24 weeks and the following
four explanatory variables: 1) high disease activity
defined as DAS28-CRP >5.1; 2) high serum IgG level; 3)
auto-antibody status (i.e., the presence or absence of RF
and/or anti-CCP antibodies), since all of them have been
found previously as associated with subsequent RTX
response [25, 26]; and 4) detectable serum IL-33. All
these explanatory variables were entered in a stepwise
multivariate model systematically adjusted on RF or
anti-CCP positivy (entry level, p = 0.15; level for staying
in the model, p = 0.10). Results are expressed as odds ra-
tios (ORs) with 95% confidence intervals (CIs). A p value
<0.05 was considered as significant. Statistical analysis
was performed with SAS 9.4 software.
Results
Characteristics of the populations
The characteristics of patients from cohort 1 are
presented in Table 1. There was no significant difference
between the 111 patients that underwent IL-33 assess-
ment and the others that participated in the main
SMART trial (n = 113) who did not (Table 1). Available
characteristics of patients from cohort 2 are presented in
Additional file 1 (Table S1).
Serum IL-33 levels
Using the validated Quantikine assay, most of the
patients had undetectable serum IL-33: 84/111 (76%) and
Table 1 Baseline characteristics of RA patients included in the IL-33 ancillary study from the SMART trial and a comparison between
the patients in the SMART cohort included in the IL-33 study (cohort 1, n = 111) and the rest of the cohort not assessed for serum
IL-33 level (n = 113)
Cohort 1 Patients in the SMART cohort
without IL-33 dosage
Whole SMART cohort Inter-group
comparison
(n = 111) (n = 113) (n = 224)
Age (years) 56 ± 11 56 ± 11 56 ± 11 0.99
Female 95 (86%) 92 (81%) 187 (84%) 0.401
Disease duration (years) 11 (1–42) 10 (0.8–45) 11 (0.8–45) 0.094
DAS28-CRP 5.8 ± 0.8 5.8 ± 0.9 5.8 ± 0.9 0.791
HAQ-DI 1.8 ± 0.6 1.8 ± 0.6 1.8 ± 0.6 0.753
Prednisone treatment 76 (68%) 88 (78%) 165 (74%) 0.11
Prednisone dosage (mg/day) 8 (2–20) 10 (2–15)* 10 (2–20)* 0.243
MTX (mg/week) 14 ± 4 14 ± 4 14 ± 4 0.351
Previous biologic: None/mAb/Eta 8 (7%)/66 (60%)/37(33%) 7 (6%)/70(62%)/36(32%) 15 (7%)/136 (61%)/73(33%) 0.914
Positive RF 76 (69%) 68 (61%) 144 (65%) 0.226
Positive anti-CCP 92 (83%) 78 (70%) 170 (76%) 0.02
Serum IgG level (g/L) 11.8 (4.6–19.2) 12 (5.4–23.3) 12 (4.6–23.3) 0.564
CRP level (mg/L) 12 (0.4–139) 11 (0.3–102) 11 (0.3–139) 0.938
Radiographic erosions 100 (90%) 98 (87%) 198 (88%) 0.432
MTX duration (years) 3.6 (0.1–20.8) 3.2 (0.3–20.5) 3.5 (0.1–20.8) 0.856
Time since last anti-TNF (months) 2.7 (0.6–64.4) 2.8 (1.2–73.6) 2.7 (0.6–73.6) 0.458
Values are shown as means and standard deviations (mean ± SD) or medians (range) for continuous data, and n (%) for qualitative data
*Some patients had a deviation protocol concerning the authorized prednisone dosage
anti-CCP anti-cyclic citrullinated peptide antibody, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, Eta etanercept, HAQ-DI Health Assessment
Questionnaire—Disease Index, IL interleukin, mAb monoclonal antibody, MTX methotrexate, RF rheumatoid factor, TNF tumor necrosis factor
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39/74 (53%) in cohorts 1 and 2, respectively. In patients
with detectable IL-33, mean serum levels were 63.39 ±
87.31 pg/mL and 45.35 ± 87.19 pg/mL in cohorts 1 and 2,
respectively (Fig. 1).
Factors associated with subsequent response to RTX at
week 24 in cohort 1
Among the 111 patients, a total of 84 patients (76%) were
classified as EULAR responders to RTX at week 24; 27 pa-
tients (24%) were non-responders. Detectable serum IL-33
was found in 27 (24.3%) patients. In univariate analysis,
the three explanatory variables including DAS28-CRP
>5.1, high serum IgG level, and auto-antibody status were
associated with RTX response and were included in the
multivariate model since they had a p value <0.15 for the
association with EULAR response (Table 2).
The multivariate analysis indicated that high disease
activity (OR 5.24, 95% CI 1.85–14.85) and auto-antibody
status (OR 3.48, 95% CI 1.04–11.60) were independently
associated with RTX response. A non-significant associ-
ation between EULAR response and high serum IgG
level was found (OR 2.82, 95% CI 0.97–8.14) (Table 2).
There was no association with serum IL-33 detection in
multivariate analysis in cohort 1.
Factors associated with subsequent response to RTX at
week 24 in cohort 2
In order to replicate these results in RA patients from
routine care, we tested whether the DAS28-CRP >5.1,
high serum IgG level, auto-antibody status, and detect-
able serum IL-33 were associated with response to RTX
in cohort 2 in which there were 73% EULAR responders
among 74 patients.
In univariate analysis, high disease activity and detect-
able serum IL-33 were associated with RTX response,
but not auto-antibody status or high serum IgG (Table 2).
In multivariate analysis, detectable serum IL-33 was the
sole factor associated with RTX response (OR 3.73, 95%
CI 1.12–12.38), with a non-significant association for
auto-antibody status (OR 32.76 (0.7– 999). The presence
of RF and anti-CCP auto-antibodies in 97% of the
patients in cohort 2 might limit analysis on these markers.
Factors associated with subsequent response to RTX at
week 24 in the combination of cohorts 1 and 2
Multivariate analyses indicated that four factors were
independently and significantly associated with response
to RTX: high disease activity (OR 4.10, 95% CI 1.90–
8.85), auto-antibody status (OR 3.27, 95% CI 1.13–9.46),
high IgG level (OR 2.32, 95% CI 1.01–5.33), and detect-
able serum IL-33 (OR 2.40, 95% CI 1.01–5.72) (Table 3
and Fig. 2). Since the presence of RF and/or anti-CCP
antibodies and high serum IgG level have already been
identified as predictive markers of subsequent EULAR
response, we aimed to investigate whether the addition
of detectable serum IL-33 increased the likelihood of
response. While 55% of patients without these three
factors responded to RTX, the presence of RF and/or
anti-CCP antibodies and elevated serum IgG level fur-
ther increased the likelihood of this response (77%
responders; OR = 2.72, 95% CI 0.67–10.98; p = 0.16 versus
patients without any of these three factors). When we
Fig. 1 Serum IL-33 levels in patients from cohort 1, cohort 2, and the combined cohorts. Dosage performed with Quantikine ELISA IL-33 kit (R&D
Systems). Each dot represents one patient; means are presented. IL interleukin
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added detectable serum IL-33 to these two factors, 100%
of the patients with the three risk factors (corresponding
to 9% of the combined population) responded to RTX
(OR 29.61, 95% CI 1.30–674.79; p = 0.034 versus patients
with none of the three risk factors) (Fig. 3).
If we restricted the analysis to seropositive patients
from both cohorts (94/111 from cohort 1 and 72/74
from cohort 2), IL-33 detection was still highly
predictive of EULAR response (OR 3.03, 95% CI
1.24–7.4; p = 0.015), confirming that this biomarker
was independent of seropositivity.
Discussion
In this study, we have identified serum IL-33 detection as
a novel biomarker associated with RTX response in RA,
in addition to auto-antibody status, in real life patients.
This study was based on our previous observation of
the upregulation of IL-33 mRNA expression in the
whole blood that was associated with RTX response in a
microarray study performed in patients randomly
selected from the SMART trial [20]. Since the IL-33 pro-
tein may be easily quantified in the serum, we first
assessed serum IL-33 levels in the same population using





Univariate p value Multivariate p value
OR (95% CI) OR (95% CI)
Cohort 1 (n = 111) DAS28-CRP 3.2–5.1 (Ref) 12 (46.2%) 14 (53.8%) 4.0 (1.55–10.36) 0.004 5.24 (1.85–14.85) 0.002
>5.1 15 (17.6%) 70 (82.4%)
RF or anti-CCP Negative (Ref) 7 (41.2%) 10 (58.8%) 2.59 (0.88–7.67) 0.08 3.48 (1.04–11.60) 0.04
Positive 20 (21.3%) 74 (78.7%)
IgG > ULN (g/L) No (Ref) 21 (30.9%) 47 (69.1%) 2.76 (1.01–7.52) 0.048 2.82 (0.97–8.14) 0.056
Yes 6 (14.0%) 37 (86.0%)
Detectable IL-33 No (Ref) 23 (27.4%) 61 (72.6%) 2.17 (0.62–6.95) 0.19 – –
Yes 4 (14.8%) 23 (85.2%)
Cohort 2 (n = 74) Disease activity
DAS28-CRP
3.2–5.1 (Ref) 14 (36.8%) 24 (63.2%) 2.92 (0.97–8.73) 0.056 – –
>5.1 6 (16.7%) 30 (83.3%)
RF or anti-CCP Negative (Ref) 2 (100%) 0 (0%) 14.72 (0.34–629.71) 0.16 32.76 (0.7–999) 0.076
Positive 18 (25.0%) 54 (75%)
IgG > ULN (g/L) No (Ref) 15 (37.5%) 25 (62.5%) 2.10 (0.58–7.57) 0.26 – –
Yes 4 (22.2%) 14 (77.8%)
Detectable IL-33 No (Ref) 14 (35.9%) 25 (64.1%) 2.71 (0.91–8.10) 0.07 3.73 (1.12–12.38) 0.03
Yes 6 (17.1%) 29 (82.9%)
Values are given as n (%) of responders or non-responders with a given characteristic
Rituximab response was evaluated at week 24 according to EULAR response
anti-CCP anti-cyclic citrullinated peptide antibody, CI confidence interval, DAS28-CRP Disease Activity Score in 28 joints by C-reactive peptide, EULAR European
League Against Rheumatism, Ig immunoglobulin, OR odds ratio, Ref referent, RF rheumatoid factor, ULN upper limit of normal (i.e., 12.7 g/L)







p value Multivariate OR
(95% CI)
p value
DAS28-CRP 3.2–5.1 (Ref) 26 (40.6%) 38 (59.4%) 3.26 (1.64–6.47) 0.0007 4.10 (1.90–8.85) 0.0003
>5.1 21 (17.4%) 100 (82.6%)
RF or anti-CCP Negative (Ref) 9 (47.4%) 10 (52.6%) 3.03 (1.15–8.001) 0.025 3.27 (1.13–9.46) 0.03
Positive 38 (22.9%) 128 (77.1%)
IgG > ULN (g/L) No (Ref) 36 (33.3%) 72 (66.7%) 2.55 (1.16–5.60) 0.02 2.32 (1.01–5.33) 0.048
Yes 10 (16.4%) 51 (83.6%)
Detectable IL-33 No (Ref) 37 (30.1%) 86 (69.9%) 2.24 (1.03–4.87) 0.04 2.40(1.01–5.72) 0.047
Yes 10 (16.1%) 52 (83.9%)
Values are given as n (%) of responders or non-responders with a given characteristic
Rituximab response was evaluated at week 24 according to EULAR response
anti-CCP anti-cyclic citrullinated peptide antibody, CI confidence interval, DAS28-CRP Disease Activity Score in 28 joints by C-reactive peptide, EULAR European
League Against Rheumatism, Ig immunoglobulin, OR odds ratio, Ref referent, RF rheumatoid factor, ULN upper limit of normal (i.e., 12.7 g/L)
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the DuoSet ELISA IL-33 kit (R&D System) and prelimin-
ary reported in an abstract that the serum IL-33 level
was associated with the RTX response [23]. However,
additional experiments in patients with Sjögren’s
syndrome or RA have raised caution about the accuracy
of this kit for sera measurements [24]. Consequently, we
discarded these preliminary results and examined serum
IL-33 again with an accurate ELISA kit (Quantikine)
validated for sera, in two separate and then merged
populations.
Here, we have found in univariate and multivariate
analysis a significant association between serum IL-33 de-
tection and EULAR response in cohort 2. Furthermore,
when we combined the two cohorts, the association was
significant with an odds ratio in the same range as high
serum IgG level (i.e., approximately 2). We thus confirmed
at the protein level the results found at the mRNA level,
which demonstrates that transcriptomic analysis with non
a-priori hypotheses might open the way to new patho-
genic pathways.
Fig. 3 Frequency of EULAR response according to the presence of auto-antibodies, the detectability of serum IL-33, and a serum IgG above the
upper limit of normal in cohort 1, cohort 2, and the combined cohorts. Results are presented for patients having auto-antibodies and/or elevated
serum IL-33 level and/or elevated serum IgG level compared with patients having no auto-antibodies, a non-elevated serum IL-33 and a non-elevated
IgG level (referent). anti-CCP anti-cyclic citrullinated peptide antibody, Ig immunoglobulin, IL interleukin, RF rheumatoid factor
Fig. 2 Association between the four explanatory variables and EULAR response at 24 weeks after the first rituximab infusion in the combination
of cohorts 1 and 2. Results from the multivariate analysis are presented as odds ratios (OR) (95% confidence intervals (CI)) for each factor. anti-CCP
anti-cyclic citrullinated peptide antibody, DAS28-CRP Disease Activity Score in 28 joints by C-reactive peptide, IL interleukin, RF rheumatoid factor
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This association was independent of strong predictive
factors associated with RTX response, especially the
presence of RF or anti-CCP antibodies, which
strengthens the possible interest in serum IL-33 assess-
ment. We previously reported that patients with a pres-
ence of auto-antibodies and high serum IgG level had a
better response to RTX in comparison with patients
having none of these characteristics [25]. If serum IL-33
detection is added to these two predictive factors, the
likelihood of response to RTX reaches 29.6 (95% CI 1.3–
675) in comparison with absence of these three factors.
Indeed, 100% of patients displaying these three factors
simultaneously were responsive to RTX in our combined
cohort. However, these patients represented 9% of the
study population.
Auto-antibody status was associated with RTX response
in SMART, as previously reported [25], but also in the
combination of cohorts. The absence of association in
cohort 2 alone may be explained by the presence of these
auto-antibodies in almost all the patients (97%) limiting
analysis on these markers. Lastly, as in every trial, it is
easier to have a response when the starting DAS28 is high
and high disease activity was associated with a better
response to RTX, as previously observed in SMART [25].
Despite a number of strengths, and especially the use
of a replication cohort, this study has several limitations.
First, serum IL-33 assessment needs the use of an accur-
ate assay such as the Quantikine kit, but the relatively
low frequency of patients with detectable IL-33 level
(33.5% in the merged population) justifies qualitative IL-
33 detection rather than quantitative IL-33 values. Sec-
ond, we have no data on the association between serum
IL-33 detection and response to other biologic agents in
RA, limiting our findings to RTX. Third, the association
between serum IL-33 detection and response to RTX is
statistically significant, but the usefulness of such a
measurement for clinical practice needs to be further in-
vestigated. Finally, the presence of RF and anti-CCP
auto-antibodies in 97% of the patients in cohort 2 might
limit analysis on these markers, as well as the difference
in terms of high disease activity (DAS 28-CRP >5.1)
frequency between the two cohorts (cohort 1 = 77%
versus cohort 2 = 49%).
Conclusions
In conclusion, serum IL-33 assessment with a robust
assay may represent a novel, easy biomarker predicting
RTX response in synergy with auto-antibody status and
high serum IgG level. Such a finding concerning these
three biomarkers being easy to monitor in clinical prac-
tice represents a further step towards the goal of person-
alized medicine to determine the best approach to the
therapeutic management of RA [27].
Additional file
Additional file 1: Table S1. Baseline characteristics of RA patients from
Clermont and from Leeds. (DOC 33 kb)
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